Fact sheet: BB Medtech

Fund information
Fund name
BB Medtech T EUR
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund managers
  • Stefan Blumsince 29/09/2009
  • John Manierisince 01/03/2016
  • Marcel Fritschsince 29/09/2009
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the medtech sector and who are willing to accept the equity risk typical of this sector.
Benchmark
  • MSCI Healthcare Equip. & Supp
Investment style
None
Investment method
Shares
Quick stats
1 Year return
27.7%
1 Year rank in sector
-
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.91%
Fund size
£135m (£145m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
121
Top in this sector
Fund name1 Year
Polar Capital Biotechnology30.1%
BB Medtech27.7%
Franklin Biotech Disc22.4%
Wellington GlHthcrEq20.4%
UBS (L)E-Btech$19.2%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA84.2%
    Denmark4.1%
    UK3%
    Money Market2.6%
    France2.4%
  • Health Care78.4%
    Others15.1%
    Biotechnology/Medical4.7%
    Money Market1.8%
  • US Equities84.2%
    Danish Equities4.1%
    UK Equities3%
    Money Market2.6%
    French Equities2.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund5.2%8.3%6.7%27.7%66.9%117.9%
Sector5.8%4.7%3.3%15%21.8%106.4%
Rank within sector------
Quartile
Calendar performance
 YTD - 20172016201520142013
Fund8.4%6.9%11.3%36%16%
Sector8.7%-9.9%7.2%28.1%41%
Rank within sector-----
Quartile
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
12.89
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.71
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
1.01
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.22
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
10.09
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
1.06
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.64
Price movement
52 week high85.9
52 week low67.7
Current bid price-
Current offer price-
Current mid price85.77
Region
1USA84.2%
2Denmark4.1%
3UK3%
4Money Market2.6%
5France2.4%
6Germany1.6%
7Canada1.1%
8Japan1%
Industry sector
1Health Care78.4%
2Others15.1%
3Biotechnology/Medical4.7%
4Money Market1.8%
Asset type
1US Equities84.2%
2Danish Equities4.1%
3UK Equities3%
4Money Market2.6%
5French Equities2.4%
6German Equities1.6%
7Canadian Equities1.1%
8Japanese Equities1%
Individual holdings
1ABBOTT LABORATORIES8.7%
2BOSTON SCIENTIFIC CORP7.4%
3MEDTRONIC INC7.3%
4DANAHER CORP6.6%
5ZIMMER BIOMET HLDGS INC5.1%
6STRYKER CORP4.7%
7EDWARDS LIFESCIENCES CORP4.6%
8BAXTER INTERNATIONAL INC4.3%
9GN STORE NORD3.7%
Management
Fund manager group
Bellevue Asset Management
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the medtech sector and who are willing to accept the equity risk typical of this sector.
Benchmark
  • MSCI Healthcare Equip. & Supp
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Stefan Blum29/09/2009Stefan Blum is the Lead Portfolio Manager of the BB Medtech (Lux) Fund. He has 13 years of experience in the healthcare sector. Prior to joining Bellevue Asset Management he spent 4 years as head of investor relations at Sonova, the world's largest manufacturer of hearing instruments. As a financial analyst at Bank Sarasin from 1996 to 2000, he covered medical technology and other stocks. Before that he served as CFO of Obtree Technologies Inc. and advised Swiss listed companies on strategic investor relations issues. Stefan Blum obtained a degree in business administration/economics from the University of St. Gallen and is a graduate of AZEK.
John Manieri01/03/2016
Marcel Fritsch29/09/2009Marcel Fritsch is a Portfolio Manager of the BB Medtech (Lux) Fund. He was previously a consultant with Deloitte, a position he held for more than 3 years. In this function he provided multinational companies in medical technology, pharmaceutical and manufacturing sectors with support on strategic issues. Devising corporate strategy concepts, optimizing organizational structures and assessing the value of business entities in connection with corporate transactions were among his duties. Marcel Fritsch holds a degree in business administration/economics from the University of St. Gallen (HSG).
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Germany, Spain, United Kingdom, Luxembourg, Offshore
BB Medtech B CHF
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price240.7
CurrencyCHF
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX2
BB Medtech B EUR
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price341.85
CurrencyEUR
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX0
BB Medtech B USD
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price250.92
CurrencyUSD
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX1
BB Medtech HB CHF
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price230.97
CurrencyCHF
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMSS5
BB Medtech HB EUR
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price274.54
CurrencyEUR
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMSS4
BB Medtech I CHF
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.56%
Total expense ratio (TER)1.56%
Bid price-
Offer price-
Mid price254.67
CurrencyCHF
Price updated17/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX3
BB Medtech I EUR
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.57%
Bid price-
Offer price-
Mid price361.85
CurrencyEUR
Price updated17/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX4
BB Medtech I GBP
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.56%
Total expense ratio (TER)1.56%
Bid price-
Offer price-
Mid price282.06
CurrencyGBP
Price updated17/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi code10KJ
BB Medtech I USD
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.57%
Bid price-
Offer price-
Mid price264.45
CurrencyUSD
Price updated17/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX5
BB Medtech T CHF
Initial charge-
Annual charge1.2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.91%
Total expense ratio (TER)1.91%
Bid price-
Offer price-
Mid price90.78
CurrencyCHF
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX6
BB Medtech T EUR
Initial charge-
Annual charge1.2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.91%
Total expense ratio (TER)1.91%
Bid price-
Offer price-
Mid price85.77
CurrencyEUR
Price updated17/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGSK9
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.